# A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

> **NCT06672523** · PHASE1 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 8 (estimated)

## Conditions studied

- Advanced Solid Tumors With Homozygous MTAP Deletion

## Interventions

- **DRUG:** BMS-986504
- **DRUG:** [14C]-BMS-986504

## Key facts

- **NCT ID:** NCT06672523
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2026-04-20
- **Final completion:** 2026-04-20
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672523, "A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06672523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*